| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/10/2002 | WO2001014420A3 Novel members of the plexin family and uses thereof |
| 05/10/2002 | WO2001002000A3 Method and composition for affecting reproductive systems |
| 05/10/2002 | WO2001000877A3 Method of isolation of regulated virulence determinants from bacterial pathogens |
| 05/10/2002 | WO2001000246A3 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 05/10/2002 | WO2000067761A8 Compositions and methods for identifying antigens which elicit an immune response |
| 05/10/2002 | WO2000067736A3 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | CA2783639A1 Active variants of fgf with improved specificity |
| 05/10/2002 | CA2463623A1 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy |
| 05/10/2002 | CA2431332A1 Compositions and methods for prolonging survival of chilled platelets |
| 05/10/2002 | CA2428023A1 Methods and compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
| 05/10/2002 | CA2428012A1 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |
| 05/10/2002 | CA2427858A1 Compositions for inhibiting grb7 |
| 05/10/2002 | CA2427850A1 Interferons, uses and compositions related thereto |
| 05/10/2002 | CA2427802A1 Methods and compositions for the diagnosis of cancer susceptibilites and defective dna repair mechanisms and treatment thereof |
| 05/10/2002 | CA2427800A1 Prokineticin polypeptides, related compositions and methods |
| 05/10/2002 | CA2427795A1 Sustained release device for treating conditions of the joint |
| 05/10/2002 | CA2427731A1 Gnrh analogues for treatment of urinary incontinence |
| 05/10/2002 | CA2427659A1 Methods for producing and improving therapeutic potency of binding polypeptides |
| 05/10/2002 | CA2427629A1 Gene regulation therapy involving ferritin |
| 05/10/2002 | CA2427572A1 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | CA2427557A1 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | CA2427537A1 Use of enzymes obtained from ciliates as medicaments for promoting digestion |
| 05/10/2002 | CA2427535A1 Use of blood coagulation factor xiii for treating haemophilia a |
| 05/10/2002 | CA2427533A1 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2427257A1 Expression vectors able to elicit improved immune response and methods of using same |
| 05/10/2002 | CA2427194A1 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | CA2427193A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/10/2002 | CA2427047A1 Mineralized collagen-polysaccharide matrix for bone and cartilage repair |
| 05/10/2002 | CA2426992A1 Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses |
| 05/10/2002 | CA2426762A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | CA2426658A1 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 05/10/2002 | CA2426200A1 Inhibition or reversal of skin aging by actin-sequestering peptides |
| 05/10/2002 | CA2426047A1 Therapeutic oligonucleotides of reduced toxicity |
| 05/10/2002 | CA2426012A1 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements |
| 05/10/2002 | CA2425842A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 05/10/2002 | CA2425627A1 Kahalalide f |
| 05/10/2002 | CA2425583A1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 05/10/2002 | CA2424932A1 Cd36 as a heat shock protein receptor and uses thereof |
| 05/10/2002 | CA2395324A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | WO2002036153A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | US20020056144 Transgenic animal models for cardiac hypertrophy and methods of use thereof (screening) |
| 05/09/2002 | US20020055627 Nucleotide sequences coding cancer antigens for use in the detection treatment and prevention of cancer of colon and/or rectum |
| 05/09/2002 | US20020055617 Cloning and recombinant production of cfr receptor(s) |
| 05/09/2002 | US20020055616 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 05/09/2002 | US20020055615 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology |
| 05/09/2002 | US20020055614 Immune reactivity to her-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated |
| 05/09/2002 | US20020055522 Treatment of thrombotic diseases, asthma, emphysema, cirrhosis, arthritis, carcinoma, melanoma, restenois, atheroma, trauma, shock and reperfusion injury. |
| 05/09/2002 | US20020055500 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds |
| 05/09/2002 | US20020055496 Formulation and system for intra-oral delivery of pharmaceutical agents |
| 05/09/2002 | US20020055492 Recognizes the extracellular domain of the human IFN-R and which has neutralizing capacity against the biological properties of human type I-IFN. |
| 05/09/2002 | US20020055483 Treating hepatitus B, C and D; AIDS; antiproliferative agents |
| 05/09/2002 | US20020055482 Molecular constructs with a carcinoembryonic antigen (cea) transcriptional regulatory sequence |
| 05/09/2002 | US20020055481 DNA that represents the splicing enhancer sequence (SES) in exon 45 of human dystrophin gene, and serves as a template in preparation of the antisense oligonucleotide, which is used to induce exon 45 skipping |
| 05/09/2002 | US20020055480 SOX-9 gene and protein and use in the regeneration of bone or cartilage |
| 05/09/2002 | US20020055479 Treating type 2 diabetes, metabolic disorders, obesity and cancer. |
| 05/09/2002 | US20020055478 Monitoring 103P3E8 gene products in a biological sample from a patient who has or who is suspected of having cancer and comparing the gene expression products with that of a normal sample |
| 05/09/2002 | US20020055476 RAMPs are small proteins that transport calcitonin-receptor-like proteins to the plasma membrane; drug screening |
| 05/09/2002 | US20020055474 Novel molecules of the tnf ligand superfamily and uses therefor |
| 05/09/2002 | US20020055468 By administering a polypeptide of given amino acid sequence |
| 05/09/2002 | US20020055467 Truncated neublastin, of the glial cell-derived nerve growth factor (GDNF) subfamily; when dimerized, binds to a RET (a receptor tyrosine kinase) polypeptide |
| 05/09/2002 | US20020055466 Terpolymer of tyrosine, alanine and lysine randomly polymerized into a polypeptide |
| 05/09/2002 | US20020055464 Polyacid glycopeptide derivatives |
| 05/09/2002 | US20020055463 Peptidomimetics for Grb2 (growth factor receptor binding protein); treating cancer, metastasis and proliferative disorders |
| 05/09/2002 | US20020055461 Stable polymer aqueous/aqueous emulsion system and uses thereof |
| 05/09/2002 | US20020055460 Adminstering a compound that binds to a receptor for the glucagon-like peptide-1 (GLP-1) |
| 05/09/2002 | US20020055419 System and method to improve fitness training |
| 05/09/2002 | US20020055174 Complex for transferring an anionic substance of interest into a cell |
| 05/09/2002 | US20020055169 Method for expression of heterologous proteins in yeast |
| 05/09/2002 | US20020055160 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/09/2002 | US20020055159 23680,a novel human aminotransferase and uses therefor |
| 05/09/2002 | US20020055158 Human tissue inhibitor of metalloproteinase-4 |
| 05/09/2002 | US20020055157 Nucleotide sequences coding polypeptide for use in the treatment of cell differentiation, proliferation and migratory defects |
| 05/09/2002 | US20020055156 Zsig33-like peptides |
| 05/09/2002 | US20020055147 Nucleotide sequences coding cytokine; for use in the treatment of immunological defects, allergies, asthma and arthritis |
| 05/09/2002 | US20020055145 Isolating preferential polypeptide; obtain sample, incubate with ion exchange resin, elute, recover polypeptide |
| 05/09/2002 | US20020055144 Human hematopoietic-specific protein |
| 05/09/2002 | US20020055142 Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies |
| 05/09/2002 | US20020055140 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis |
| 05/09/2002 | US20020055139 Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| 05/09/2002 | US20020055138 Staphylococcal GTPase obg nucleotide sequence encoding Staphylococcal GTP-binding protein |
| 05/09/2002 | US20020055137 Methods for detecting nucleic acid molecules encoding flh2882, a GPCR showing homology to the 5HT family of receptors |
| 05/09/2002 | US20020055131 Use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and thioredoxin stimulated cell growth |
| 05/09/2002 | US20020055129 Antibodies for the alpha platelet-derived growth factor receptor |
| 05/09/2002 | US20020055122 Administering to the recipient mammal for promoting acceptance of graft, an inhibitor of the CD40/ ligand- CD40 costimulatory interaction; introducing into the recipient mammal, hematopoietic stem cells and implanting the graft |
| 05/09/2002 | US20020055121 Combining a sample from human host with antibodies or antibody fragments which bind specificallly to a peptide having preferential amino acid sequence and detecting the formation of immune complexes indicative of melanoma cells |
| 05/09/2002 | US20020054917 Compositions comprising beta glucan and lactoferrin, and methods for their use |
| 05/09/2002 | US20020054916 Comprising ceruloplasmin and a serum-derived composition (SDF) having a low molecular weight, electrically charged at acidic pH and having absorption at 280 mn, capable of inducing terminal cell differentiation of leukemic cells |
| 05/09/2002 | US20020054902 Liposomes containing therapeutic genes are conjugated to targeting agents to provide transport of encapsulated gene across blood-retainal barrier and plasma membrane of ocular cell, where this gene expresses encoded therapeutical agent |
| 05/09/2002 | US20020054887 Toxin has at least one amino acid change and is substantially non-lethal compared with wild type SPE-A toxin; for vaccines |
| 05/09/2002 | US20020054882 Anti-human influenza virus antibody |
| 05/09/2002 | US20020054881 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites |
| 05/09/2002 | US20020054880 Suppressing inflammatory response in mammal by the administration of lectin derived carbohydrate binding peptide capable of binding terminally linked alpha-sialic acid derivative |
| 05/09/2002 | US20020054879 Reacting protein with polysaccharide to produce mixture including protein-polysaccharide conjugate and free protein |
| 05/09/2002 | US20020054878 Anti-IgE antibodies |
| 05/09/2002 | US20020054874 Exposing cells having the trk (neurotrophin) receptor to a multivalent immunoglobulin which binds to the receptor and activates the receptor by inducing increase in phosphorylation of the receptor |
| 05/09/2002 | US20020054873 Attenuating the tumor cells, introducing a nucleic acid molecule which encodes and OX-40 receptor binding agent which is expressed on the surface of tumor cells, administering the above preperation |
| 05/09/2002 | US20020054872 Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| 05/09/2002 | US20020054871 Treating a host suffering from hyperlipidemia resulting from elevated levels of at least one of very low density lipoproteins and triglycerides and effective amount of an agent that reduces the level of active apolipoprotein E |